Envoy Medical signs Atlas lawsuit dismissal agreement

The agreement calls for dismissal of all claims with prejudice and requires no payment by Envoy Medical or the other defendants.

Rhea-AI Filing Summary

Envoy Medical, Inc. (COCH) entered into a Dismissal Agreement with Atlas Merchant Capital SPAC Fund I LP on October 6, 2026, concerning litigation in the Delaware Court of Chancery. Under the agreement, all of Atlas’ claims will be dismissed with prejudice, and there will be no further proceedings. Envoy Medical and the other defendants are not required to make a payment to Atlas under the agreement.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Dismissal Agreement, with prejudice, Court of Chancery

3 terms

Dismissal Agreement regulatory

"entered into a Dismissal Agreement"

with prejudice regulatory

"claims will be dismissed with prejudice"

A legal phrase meaning a claim, lawsuit, or right is closed permanently and cannot be brought again; it signals finality in a dispute. For investors, 'with prejudice' matters because it removes the chance of the same legal exposure reappearing, similar to locking a door so no one can enter again, which can reduce uncertainty about future liabilities and affect valuation and risk assessments.

Court of Chancery regulatory

"litigation in the Delaware Court of Chancery"

A court of chancery is a specialized judicial body that decides disputes about fairness and the proper behavior of people who run companies, such as conflicts over mergers, trusts, or directors’ duties. It can order remedies like blocking a deal or forcing changes instead of just awarding money, so its decisions can swiftly affect company control, deal timelines, and shareholder value — like a referee enforcing the rules in complex corporate contests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Envoy Medical-Atlas dismissal agreement provide?

Envoy Medical agreed with Atlas Merchant Capital SPAC Fund I LP that all of Atlas’ claims will be dismissed with prejudice, with no further proceedings and no payment required from Envoy Medical or any other defendant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 09:00 AM Accepted by SEC EDGAR 10/07/2026 - 09:00 AM Learn about SEC filing dates

false 0001840877 0001840877 2026-10-06 2026-10-06 0001840877 COCH:ClassCommonStockParValue0.0001PerShareMember 2026-10-06 2026-10-06 0001840877 COCH:RedeemableWarrantsEachWholeWarrantMember 2026-10-06 2026-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2026

ENVOY MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40133		86-1369123
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4875 White Bear Parkway White Bear Lake, MN		55110
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 900-3277

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share		COCH		The Nasdaq Stock Market LLC
Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share		COCHW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 6, 2026, Envoy Medical, Inc., a Delaware corporation (the “Company”), entered into a Dismissal Agreement (the “Dismissal Agreement”) regarding litigation in the Delaware Court of Chancery (the “Litigation”) with Atlas Merchant Capital SPAC Fund I LP (“Atlas”) related to Atlas’ allegation that it was not allowed to redeem its shares of Class A Common Stock in the Company’s September 2023 business combination transaction.

Pursuant to the terms of the Dismissal Agreement, all of Atlas’ claims will be dismissed with prejudice, and there will be no further proceedings in relation to the Litigation. In addition, neither the Company nor any other defendant will be required to make a payment to Atlas under the Dismissal Agreement.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENVOY MEDICAL, INC.
October 7, 2026	By:	/s/ Brent Lucas
		Brent Lucas
		Chief Executive Officer

2

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.7 KB
• EX-101 XBRL DEFINITION FILE 26.0 KB
• EX-101 XBRL LABEL FILE 35.8 KB
• EX-101 XBRL PRESENTATION FILE 24.7 KB